<DOC>
	<DOCNO>NCT01409200</DOCNO>
	<brief_summary>The goal clinical research study learn add axitinib hormonal therapy help control prostate cancer give surgery . The safety drug also study .</brief_summary>
	<brief_title>Neoadjuvant Axitinib Prostate Cancer</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( roll dice ) 1 2 group : - If Group A , receive axitinib hormonal therapy . - If Group B , receive hormonal therapy alone . You 2 3 chance place Group A . You 1 3 chance place Group B . Study Drug Administration : All participant receive hormonal therapy . The hormonal drug receive standard care hormone therapy . The study doctor decide hormone therapy receive explain take hormone therapy risk . You 8 week hormone therapy assign study group . After assigned study group , receive 4 month hormone therapy . If Group A , also take 1 capsule axitinib mouth 2 time day . You ask take blood pressure 2 time week record diary take axitinib dose . Note : If blood pressure 150 systolic ( upper number ) OR 100 diastolic ( low number ) develop symptom relate increase blood pressure please contact study doctor immediately . You take blood pressure home elsewhere , drug store doctor office . Doses take 12 hour apart time day , food . If miss dose , may take 3 hour late next schedule dose ; otherwise make miss dose . Instead , skip miss dose take next dose schedule . If vomit time take dose make , instead take next dose schedule . You ask keep diary help keep track take dose study drug . Record miss vomited dos diary . Bring diary visit . Each cycle 30 day . You return unused study drug and/or empty pill bottle end cycle . Study Visits : At every visit , ask side effect drug may take . About 8 week begin hormonal therapy : - Your medical history record . - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 3-4 teaspoon ) draw routine test check PSA . Your blood also test level certain protein . - You ultrasound-guided biopsy prostate 10-12 sample collect . °You separately consent biopsy , describe procedure risk detail . - Blood ( 2 tablespoon ) draw routine test . Your blood also test check thyroid function ( Group A ) . - Urine collect routine test ( Group A ) . - You ECG ( Group A ) . On Day 15 Cycle 1 ( Group A ) : - Your vital sign weight measure . - Blood ( 3-4 teaspoon ) draw routine test . On Day 1 Cycles 2 3 ( Group A ) : - Your medical history record . - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 3-4 teaspoon ) draw routine test check PSA testosterone level . Part blood use check thyroid function ( Cycle 2 ) . - Urine collect routine test About 2 month surgery ( Group B ) : - Your medical history record . - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 2 teaspoon ) draw check PSA testosterone level . About 2 week surgery go study early : Y°our medical history record . - You physical exam , include measurement weight vital sign . - You digital rectal exam . - Your performance status record . - Blood ( 3-4 teaspoon ) draw routine test check PSA testosterone level . Your blood also test level certain protein . - You CT scan MRI scan chest , abdomen , pelvis check status disease . - You bone scan check status disease . - Blood ( 2 tablespoon ) draw routine test . Your blood also test check thyroid function ( Group A ) . Length Study : You may receive study drug ( ) 6 month . You take study early disease get bad , intolerable side effect , study doctor think best interest stop . Your participation study complete follow-up visit surgery . Surgery : After 6 month study treatment , surgery remove prostate . You ask sign separate consent form surgery , risk discuss . Long-Term Follow-Up : At 1 month surgery : - You ask drug treatment may receive ( include over-the-counter drug , herbal remedy , vitamin , and/or supplement ) . - You ask side effect . - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 2 teaspoon ) draw PSA testosterone level . - If Group A , blood ( 2 tablespoon ) draw routine test check thyroid function . At 3 month surgery : - Your medical history record . - You ask disease-related symptom and/or side effect may . - You physical exam , include measurement weight , height , vital sign . - Your performance status record . - Blood ( 3-4 teaspoon ) draw routine test check PSA testosterone level . You follow-up visit every 3 month first year , every 4 month second year , every 6 month third fifth year , 1 time year unless disease worsens , start take hormone therapy , begin radiation treatment . At visit , blood ( 3-4 teaspoon ) draw routine test check PSA testosterone level . This investigational study . Axitinib FDA approve commercially available . Axitinib currently use research purpose . Up 72 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Patients adenocarcinoma prostate opinion urologist could resect response systemic therapy . Ductal adenocarcinoma permit . 2 . Patients must regard acceptable surgical risk radical prostatectomy confirm intention undergo radical prostatectomy end presurgical therapy . 3 . ECOG performance status 2 well . 4 . 4 . All patient must thorough tumor stag meet least one follow criterion : . Either lymph node biopsy lymph node dissection demonstrate lymph node metastasis prostate cancer ; b. Nonbulky ( &lt; 5 cm ) regional pelvic distant lymphadenopathy visualize CT/MRI scan . Lymph node biopsy require &lt; 2.0 cm atypical distribution . c. Primary tumor Gleason score &gt; /= 8 serum PSA concentration &gt; /=25 ng/mL , indicate high risk occult lymph node metastasis . d. Primary clinical tumor stage T3 Gleason score &gt; /= 7 , indicate high risk occult lymph node metastasis . e. Primary tumor stage T4 , indicate high risk occult lymph node metastasis . Patients group le 3 site nonpredominantly lytic bone metastasis still consider eligible trial . The 2010 AJCC stag system follow . 5 . Prior hormonal therapy ( LHRH agonist/antagonist without antiandrogen ) 8 week permit . 6 . Patients must adequate bone marrow function define absolute peripheral neutrophil count ( ANC ) &gt; /= 1,500/mm^3 platelet count &gt; /= 100,000/mm^3 ; adequate hepatic function define total bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , AST/ALT &lt; /= 2.5 x ULN ; adequate renal function define serum creatinine &lt; /= 1.5 x ULN clearance &gt; /= 60 mL/min ( measure calculate ) ; urinary protein &lt; 2+ urine dipstick ( &gt; /= 2+ , 24hour urine protein must show protein &lt; 2 g per 24 hour ) . 7 . Patients partner must surgically sterile must agree use effective contraception receive study treatment least 3 month thereafter . The definition effective contraception agreement local regulation base judgment principal investigator designate associate . 8 . Patients must sign current IRB approve informed consent indicate aware investigational nature study , keep policy institution , willing able comply schedule visit , treatment plan , laboratory test , study procedure . 9 . All patient must surgical medical oncology consult prior sign inform consent . 1 . Patients biopsyproven small cell sarcomatoid histology . 2 . Patients clinical radiological evidence bone ( &gt; /= 3 site , predominantly lytic &lt; 3 ) extranodal metastasis . 3 . Patients prior chemotherapy , experimental agent prostate cancer , patient receive 8 week prior hormone therapy exclude . 4 . Gastrointestinal abnormality inability take oral medication ; requirement intravenous alimentation ; prior surgical procedure affect absorption include total gastric resection ; treatment active peptic ulcer disease past 6 month ; active gastrointestinal bleeding evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy ; malabsorption syndrome . 5 . Anticipated need treatment drug know potent CYP3A4 inhibitor ( i.e. , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir delavirdine ) . Grapefruit juice also CYP3A4 inhibitor . 6 . Anticipated need treatment drug know CYP3A4 CYP1A2 inducer ( i.e . carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John 's wort ) . 7 . Patients infectious process , opinion investigator , could worsen outcome affected result investigational therapy . 8 . Patients symptomatic congestive heart failure , unstable angina myocardial infarction , coronary/peripheral artery bypass graft repair , cerebrovascular accident transient ischemic attack 12 month prior randomization ; deep vein thrombosis pulmonary embolism 6 month prior randomization . 9 . Persistently uncontrolled diabetes mellitus , oxygendependent lung disease , chronic liver disease , HIV infection . 10 . Inadequately control hypertension ( define systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) despite antihypertensive medication , prior history hypertensive crisis hypertensive encephalopathy . 11 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 12 . Anticipation need major surgical procedure course study outline protocol . 13 . History abdominal fistula gastrointestinal perforation within 6 month prior randomization . 14 . Serious , nonhealing wound , active ulcer , untreated bone fracture ; bone fracture must heal . 15 . Known hypersensitivity component axitinib prior use axitinib . 16 . Second malignancy ( exclude nonmelanoma skin cancer ) unless treat curative intent diseasefree 3 year . 17 . Overt psychosis , mental disability , otherwise incompetent give inform consent , history noncompliance . 18 . Planned participation experimental drug study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Adenocarcinoma prostate</keyword>
	<keyword>Ductal adenocarcinoma</keyword>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>ADT</keyword>
	<keyword>Hormonal therapy</keyword>
	<keyword>Suspected lymph node metastasis</keyword>
	<keyword>TxN1M0 TxNxM1a</keyword>
	<keyword>Progression-free</keyword>
	<keyword>Pathologic complete response</keyword>
	<keyword>pCR</keyword>
	<keyword>Systemic therapy</keyword>
	<keyword>Radical prostatectomy</keyword>
	<keyword>Pelvic lymph node dissection</keyword>
	<keyword>Axitinib</keyword>
	<keyword>AG-013736</keyword>
</DOC>